Holen Sie sich die Stockscreener-App
6.24
2.50%
-0.16
Handel nachbörslich:
6.23
-0.010
-0.16%
Schlusskurs vom Vortag:
$6.40
Offen:
$6.33
24-Stunden-Volumen:
396.37K
Relative Volume:
0.91
Marktkapitalisierung:
$314.44M
Einnahmen:
$230.47M
Nettoeinkommen (Verlust:
$30.28M
KGV:
10.23
EPS:
0.61
Netto-Cashflow:
$38.86M
1W Leistung:
-17.89%
1M Leistung:
-8.10%
6M Leistung:
+24.06%
1J Leistung:
+76.27%
1-Tages-Spanne:
$6.14
$6.385
1-Wochen-Bereich:
$5.50
$6.8599
52-Wochen-Spanne:
$2.575
$7.68
Puma Biotechnology Inc Stock (PBYI) Company Profile
Firmenname
Puma Biotechnology Inc
Sektor
Branche
Telefon
(424) 248-6500
Adresse
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
6.24 | 322.50M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-10-08 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-10 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-01-17 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2019-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-11-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-11-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-17 | Eingeleitet | Goldman | Sell |
| 2018-05-11 | Bestätigt | Stifel | Buy |
| 2017-11-10 | Bestätigt | Citigroup | Buy |
| 2017-11-10 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | Bestätigt | Stifel | Buy |
| 2017-09-11 | Bestätigt | Credit Suisse | Outperform |
| 2017-07-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-06-06 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | Bestätigt | RBC Capital Mkts | Sector Perform |
Alle ansehen
Puma Biotechnology Inc Aktie (PBYI) Neueste Nachrichten
Puma Biotech (PBYI) Earnings Call Transcript - AOL.com
Puma Biotech at TD Cowen Conference: Strategic Growth and Financial Discipline - Investing.com Canada
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2025 Earnings Call Transcript - Insider Monkey
PBYI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Puma Biotechnology (PBYI) Margin Resilience Tests Bearish Earnings Forecasts In FY 2025 Results - Sahm
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by Wall Street Zen - MarketBeat
PBYI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View - TradingView
Puma Biotechnology, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PBYI) 2026-02-27 - Seeking Alpha
Earnings call transcript: Puma Biotechnology Q4 2025 beats forecasts with strong revenue growth - Investing.com India
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Puma Biotechnology Q4 Earnings Call Highlights - MarketBeat
Puma Biotechnology (NASDAQ:PBYI) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Puma Biotechnology Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Puma Biotech: Fourth Quarter Earnings Overview - Bitget
Puma Biotechnology (PBYI) Releases Q4 2025 Earnings: Revenue Beats, EPS Tops Estimates but Cash Falls - Quiver Quantitative
Puma Biotechnology Q4 Earnings Report: What Investors Need to Know - Benzinga
Puma Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Puma Biotechnology Hits New 52-Week High of $7.68, Up 120% - Markets Mojo
Puma Biotechnology Inc expected to post earnings of 23 cents a shareEarnings Preview - TradingView
Analyst Downgrade: Is The Oncology Institute Inc Equity Warrants ROE strong enoughWeekly Trend Summary & Fast Entry Momentum Alerts - baoquankhu1.vn
Puma Biotechnology to Present at TD Cowen’s 46th Annual Health Care Conference - BioSpace
Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference - lelezard.com
Dip Buying: Whats the profit margin of BBDCJuly 2025 Price Swings & AI Driven Price Forecasts - baoquankhu1.vn
Puma Biotech (PBYI) CFO awarded new RSU and option grants - Stock Titan
Will Puma Biotechnology Inc. stock maintain dividend yieldWeekly Earnings Recap & AI Enhanced Market Trend Forecasts - mfd.ru
PUMA Biotechnology (PBYI) CEO awarded new stock options and RSUs - Stock Titan
Layoff Watch: Can Puma Biotechnology Inc be the next market leaderTrade Ideas & Real-Time Sentiment Analysis - baoquankhu1.vn
Published on: 2026-02-19 23:57:17 - baoquankhu1.vn
Naya Capital Adds Masimo Shares - AOL.com
Puma Biotechnology (PBYI) to Release Earnings on Thursday - MarketBeat
Puma Biotechnology (NASDAQ:PBYI) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Re - pharmiweb.com
Puma Biotechnology sets Feb. 26 call on 2025 financial results - Stock Titan
Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - Yahoo Finance
Puma Biotechnology (NASDAQ:PBYI) Shares Pass Above 200-Day Moving AverageWhat's Next? - MarketBeat
Why Puma Biotechnology Inc. stock is popular among millennials2025 Volume Leaders & Risk Controlled Daily Trade Plans - mfd.ru
Fund Flows: Is Puma Biotechnology Inc undervalued by DCF analysisTrade Entry Report & Community Consensus Stock Picks - baoquankhu1.vn
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)February 4, 2026 - BioSpace
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule - TradingView
Puma Biotechnology reports inducement awards under Nasdaq listing rule - marketscreener.com
Puma Biotechnology (PBYI) Price Target Increased by 42.86% to 5.10 - Nasdaq
Is Puma Biotechnology Inc. stock a defensive play in 2025Quarterly Performance Summary & Real-Time Chart Pattern Alerts - mfd.ru
Investor Mood: How does Puma Biotechnology Inc. compare to its peersRisk Management & Risk Controlled Stock Alerts - baoquankhu1.vn
Universal Beteiligungs und Servicegesellschaft mbH Buys 159,200 Shares of Puma Biotechnology, Inc. $PBYI - MarketBeat
Revenue Check: Is Puma Biotechnology Inc. stock suitable for long term investing - mfd.ru
Hedge Fund Bets: Is FONAR Corporation exposed to currency risks2025 Technical Patterns & Consistent Return Strategy Ideas - baoquankhu1.vn
Surprises Report: Will Puma Biotechnology Inc benefit from rate cutsJuly 2025 Action & Verified Short-Term Plans - baoquankhu1.vn
Should You Buy Alnylam Pharmaceuticals Before Feb. 12? - AOL.com
Finanzdaten der Puma Biotechnology Inc-Aktie (PBYI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Puma Biotechnology Inc-Aktie (PBYI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| AUERBACH ALAN H | President and CEO |
Jan 06 '26 |
Sale |
5.84 |
16,938 |
98,986 |
7,163,963 |
| HUNT DOUGLAS M | See Remarks |
Jan 07 '26 |
Sale |
5.88 |
5,014 |
29,477 |
155,907 |
| HUNT DOUGLAS M | See Remarks |
Jan 06 '26 |
Sale |
5.84 |
3,973 |
23,218 |
160,921 |
| NOUGUES MAXIMO F | Chief Financial Officer |
Jan 07 '26 |
Sale |
5.88 |
6,405 |
37,655 |
193,284 |
| NOUGUES MAXIMO F | Chief Financial Officer |
Jan 06 '26 |
Sale |
5.84 |
4,540 |
26,532 |
199,689 |
3.69%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):